- Prevalence: Migraines affect ~39 million Americans (12% of the population) — one of the most disabling neurological disorders globally.
- CECD hypothesis: Neurologist Ethan Russo’s "clinical endocannabinoid deficiency" theory proposes that deficient ECS tone underlies migraine, fibromyalgia, and IBS. Lower-than-normal anandamide has been found in the CSF of chronic migraine patients.
- CGRP interaction: THC inhibits CGRP release from trigeminal nerve endings — the same neuropeptide targeted by new CGRP monoclonal antibodies (erenumab, fremanezumab).
- Acute trial: Aviram & Samuelly-Leichtag (2017) — retrospective study of 121 migraine patients: 85.1% reported decrease in migraine frequency with cannabis use.
- Inhalation for acute: 2–5 minute onset allows early-attack interruption before peak intensity; vaporising preferred over smoking.
- Edibles for prevention: 4–8 hour duration provides sustained ECS tone elevation suitable for preventive daily use at low doses.
- MOH risk: Limit acute-use days to <10/month to avoid medication overuse headache (rebound phenomenon).
Understanding Migraines
A migraine is not merely a severe headache — it is a complex neurological disorder characterised by episodic attacks of moderate-to-severe throbbing or pulsating head pain, typically unilateral, lasting 4–72 hours. Attacks are frequently accompanied by nausea, vomiting, and extreme sensitivity to light (photophobia) and sound (phonophobia). About one-third of sufferers experience an "aura" — transient neurological phenomena including visual disturbances (scintillating scotoma, fortification spectra), sensory changes, or speech difficulties — that precede or accompany the headache phase.
Migraine pathophysiology involves cortical spreading depression (CSD) — a slowly propagating wave of neuronal and glial depolarisation that underlies the aura — followed by activation of the trigeminovascular system (TGVS). Trigeminal nerve fibres surrounding cranial blood vessels release CGRP and other neuropeptides, causing dilation of meningeal blood vessels and central sensitisation of pain pathways. Serotonin fluctuations, mast cell activation in the dura, and hypothalamic changes also contribute.
Women are disproportionately affected, accounting for ~75% of migraine sufferers, likely due to hormonal modulation of CGRP release and ECS activity. Hormonal migraines (menstrual-phase attacks) represent a particularly refractory subtype.
Conventional treatment limitations: Triptans (sumatriptan, rizatriptan) are contraindicated in cardiovascular disease and cause medication overuse headache (MOH) in up to 50% of heavy users. CGRP monoclonal antibodies (erenumab, fremanezumab) are effective for prevention but cost $600–$800/month without insurance. Preventive medications (topiramate, valproate, beta-blockers, tricyclics) carry side effects including cognitive slowing, weight changes, and fatigue that cause high discontinuation rates.
The Endocannabinoid Deficiency Hypothesis
Neurologist Ethan Russo first proposed the "clinical endocannabinoid deficiency" (CECD) theory in a 2004 paper in Neuroendocrinology Letters, subsequently updated in Cannabis and Cannabinoid Research (2016). The hypothesis posits that subnormal ECS tone — driven by genetic, environmental, or stress-related factors — underlies a cluster of conditions including migraine, fibromyalgia, and irritable bowel syndrome. All three conditions share characteristics of central sensitisation, treatment resistance to conventional drugs, and overlapping comorbidity.
Supporting evidence for CECD in migraine:
- A 2007 study by Sarchielli et al. found significantly lower anandamide levels in the cerebrospinal fluid (CSF) of chronic migraine patients versus controls.
- Post-ictal elevation of anandamide has been documented in migraineurs following attacks — possibly a compensatory upregulation in response to deficient baseline levels.
- FAAH (the enzyme that degrades anandamide) polymorphisms associated with reduced FAAH activity (and thus higher anandamide) are associated with lower migraine prevalence in genetic studies.
If CECD underlies migraine, then supplementing the ECS with phytocannabinoids represents a physiologically logical intervention — raising deficient endocannabinoid tone to normal levels, not simply suppressing a symptom.
CGRP Pathway: Where Cannabis and Triptan Science Overlap
Calcitonin gene-related peptide (CGRP) is the dominant neuropeptide in migraine pathophysiology. Released from trigeminal nerve terminals, CGRP causes dilation of meningeal vessels, activates mast cells in the dura, and drives central sensitisation in the trigeminal nucleus caudalis — collectively producing the pain, hypersensitivity, and associated features of a migraine attack. The most successful new class of migraine drugs (CGRP monoclonal antibodies and gepants) works by blocking CGRP or its receptor.
THC, acting on CB1 receptors expressed on trigeminal nerve terminals, inhibits CGRP release — the same mechanistic target as the newest generation of migraine drugs, achieved through a different receptor system. Preclinical work in rodents (Akerman et al., Cephalalgia, 2013) demonstrated that systemic cannabinoids attenuate CGRP-driven trigeminovascular activation. CBD independently reduces neuroinflammation and mast cell activation in the dura, complementing THC’s CGRP-inhibitory action.
Serotonin Receptor Overlap
Triptans work by activating 5-HT1B/1D serotonin receptors, causing vasoconstriction and inhibiting CGRP release. CBD has well-documented 5-HT1A receptor partial agonism — a related but distinct serotonin receptor subtype — which contributes to its anxiolytic and pain-modulating properties. There is some evidence that 5-HT1A activity may also reduce trigeminovascular activation through a pathway parallel to but distinct from the 5-HT1B/1D mechanism of triptans.
Clinical implication: Combining cannabis with triptans could theoretically provide complementary or additive benefits through these parallel serotonin pathways. However, combining serotonergic agents carries serotonin syndrome risk. If using both, inform your neurologist. The combination has not been studied in clinical trials for migraine specifically.
Key Clinical Evidence
Aviram & Samuelly-Leichtag Retrospective Study (2017)
A retrospective study published in Pharmacotherapy by Aviram and Samuelly-Leichtag reviewed 121 adult medical cannabis patients in Israel who reported using cannabis for migraines. Key findings: 85.1% reported a decrease in migraine frequency; 12.4% reported no change; 1.7% reported increase. Cannabis reduced average monthly migraine frequency from 10.4 to 4.6 attacks — a 55.8% reduction comparable to the best preventive pharmacotherapy. Pain intensity scores also decreased significantly. Limitations include retrospective design, self-report, and lack of placebo control.
Colorado Medical Cannabis Retrospective (Rhyne et al., 2016)
A chart review of 121 patients at a Colorado medical cannabis clinic found that 85% reported migraine frequency reduction. Inhaled cannabis was most commonly used for acute attacks; edibles were more common among preventive users. A small number of patients (11.6%) reported adverse effects, most commonly sedation and increased anxiety — both manageable by dose adjustment.
Tobacco/Weed Abuse vs. Cannabis (Cuttler et al., 2020)
A mobile application-based study (Strainprint) analysed real-world data from 1,306 cannabis sessions recorded by migraine patients. Inhaled cannabis reduced headache severity by 47.3% per session on average. Concentrates provided greater relief than flower. Female patients showed greater average pain reduction than male patients. This represents the largest real-world dataset on cannabis for acute migraine to date.
Acute vs. Preventive Protocols
Acute (Abortive) Protocol
Goal: Abort or reduce the intensity of an established attack at earliest symptom onset (prodrome or first pain).
Method: Vaporised flower or concentrate. ACDC, OG Kush, or Canna-Tsu at 1–3 puffs (5–10 mg THC equivalent) at onset.
Why inhalation: 2–5 minute onset is essential — the earlier in an attack, the more effectively it can be interrupted before central sensitisation becomes established.
Dose: Start with 1 puff (approximately 2–4 mg THC). Wait 10 minutes. Take a second puff if needed. Avoid over-medicating — high THC doses can worsen nausea.
Limit: Maximum 10 acute-use days per month to avoid medication overuse headache (MOH).
Preventive Protocol
Goal: Reduce attack frequency through daily low-dose ECS tone maintenance.
Method: Oral capsule or sublingual tincture (CBD-dominant or 1:1 ratio).
Dose: 5–10 mg CBD (± 2.5 mg THC) nightly at bedtime. Increase by 5 mg CBD weekly to a target of 25–50 mg CBD daily if needed.
Why edibles/tinctures: 4–8 hour duration provides sustained anandamide elevation and stable ECS tone. Daily consistency is key — intermittent use is less effective for prevention.
Timeline: Allow 4–6 weeks of consistent use before assessing preventive efficacy. Track attacks in a migraine diary.
Best Strains for Migraines
| Strain | Type | THC % | CBD % | Why It Helps Migraines |
|---|---|---|---|---|
| OG Kush | Hybrid (Indica-dom) | 19–26% | <1% | Potent CB1 CGRP inhibition; body relaxation eases tension; calming effect counters photophobia anxiety; acute use |
| ACDC | Hybrid (Sativa-dom) | 1–6% | 14–20% | High CBD raises anandamide; reduces CGRP-linked inflammation; minimal psychoactivity; daytime/preventive use |
| Canna-Tsu | Hybrid | 6–11% | 8–12% | Balanced 1:1; entourage effect with myrcene terpenes adding analgesic + sedative benefit; acute + preventive |
| Harlequin | Sativa-dom Hybrid | 7–15% | 8–10% | ~5:2 CBD:THC; clear-headed relief; anti-anxiety; functional daytime pain management |
| Purple Kush | Indica | 17–22% | <1% | Deep sedation for severe nocturnal migraines; myrcene + linalool supports sleep onset and pain dampening |
| Blue Dream | Sativa-dom Hybrid | 17–24% | 1–2% | Broad-spectrum relief; popular for prodrome and aura phases before full pain onset; mood uplift counters aura anxiety |
Delivery Methods
| Method | Onset | Duration | Best For |
|---|---|---|---|
| Dry-herb vaporiser | 2–5 min | 1–3 hrs | Acute attack abortion; fast onset without combustion byproducts; preferred over smoking |
| Smoking (flower) | 2–10 min | 1–2 hrs | Fast acute relief; combustion byproducts may worsen nausea in some — vaporiser is preferable |
| Sublingual tincture | 15–45 min | 2–4 hrs | Precise dosing; prodrome phase; mild-to-moderate attacks; preventive when used consistently |
| Oral capsule/edible | 45–120 min | 4–8 hrs | Preventive daily use; sustained ECS tone; not suitable for acute attacks due to slow onset |
| Topical (temple/neck) | 15–45 min | 2–4 hrs | Localised tension relief; scalp/neck muscle tightness; no systemic effect; adjunct therapy |
Medication Overuse Headache: The MOH Risk
Medication overuse headache (MOH), also called rebound headache, occurs when pain medications are used too frequently — typically more than 10–15 days per month. The brain’s pain-processing systems become sensitised to the absence of the medication, triggering headaches as levels fall. MOH has been most clearly documented for triptans (10+ days/month) and opioids, but some researchers raise concern for cannabis as well.
Evidence for cannabis-specific MOH is limited — it is much less well-established than for triptans. However, prudent clinical guidance is to limit acute cannabis use to fewer than 10 days per month for patients prone to chronic daily headache. Daily low-dose preventive use (at a consistent dose without escalation) carries much lower MOH risk than high-dose acute use on frequent days.
Migraines by Type: Tailoring Cannabis Treatment
Menstrual Migraines
Menstrual migraines — triggered by the oestrogen drop preceding menstruation — are among the most refractory and severe migraine subtype. The ECS interacts with sex hormones: oestrogen positively regulates FAAH expression, meaning as oestrogen falls pre-menstrually, FAAH decreases and anandamide levels rise — a compensatory but often insufficient response. THC and CBD during the perimenstrual window can supplement this endocannabinoid elevation. CBD-dominant formulations (to avoid cycle disruption from high THC) are preferable for the 3–5 day perimenstrual prevention window.
Chronic Daily Migraine
Chronic daily migraine (>15 headache days/month) often involves central sensitisation and frequently has medication overuse headache (MOH) from prior analgesic or triptan use. Cannabis for CDM requires a preventive-focused approach: consistent daily low-dose CBD (25–50 mg) with minimal acute use to avoid compounding MOH risk. A headache neurologist should be involved in any cannabis plan for CDM.
Vestibular Migraine
Vestibular migraine — with prominent vertigo, dizziness, and balance disruption — is the second most common cause of episodic vertigo. CBD’s anti-nausea and vestibular-stabilising properties are particularly relevant. High-THC products may worsen vestibular symptoms in some patients. CBD-dominant formulas are strongly preferred for vestibular migraine specifically.
Qualifying for Medical Cannabis: Migraines
Migraines are explicitly listed as qualifying conditions in several US states, including Michigan, Maryland, New Mexico, and Louisiana. In states with broad "debilitating condition" language (California, New York, Florida), any physician can certify migraine if they believe cannabis would be beneficial. Documentation typically needed: ICD-10 migraine codes, treatment history showing inadequate response to at least one conventional treatment, and a physician certification form. Check our state guide for current programme details.
Frequently Asked Questions
Can I take cannabis and sumatriptan at the same time?
There are no known dangerous direct interactions between cannabis and triptans. Both have serotonergic activity through different receptor subtypes, but the combination has not been associated with serotonin syndrome in published case reports. Many migraine patients use both — inhaled cannabis at attack onset, followed by a triptan if cannabis alone does not abort the attack. Inform your neurologist about combined use so they can monitor for unexpected side effects.
Does cannabis work better than triptans for migraines?
Current evidence does not support cannabis as superior to triptans for most patients. Triptans have stronger Phase III trial data for acute migraine. Cannabis may be preferred by patients who cannot use triptans (cardiovascular contraindications), have inadequate triptan response, experience significant triptan side effects, or need preventive rather than acute management. A combined approach — cannabis first-line, triptan as rescue — is used by many patients and is a reasonable strategy.